Six months neoadjuvant imatinib improves resectability potential of gastric stromal tumors in Egyptian patients

International Journal of Surgery

Volumn 8, Issue 2, 2010, Pages 105-108

  Saied, Gamal M ^a   Kensarah, Ahmed M ^b  

^a CAIRO UNIVERSITY   (Egypt)

^b KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

Author keywords

Gastrointestinal stromal tumor; GISTs; Imatinib; Neoadjuvant therapy; Targeted therapy kit (Cd117)

Indexed keywords

IMATINIB; STEM CELL FACTOR RECEPTOR;

ABDOMINAL DISCOMFORT; ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RISK; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; EGYPT; ELECTIVE SURGERY; EMERGENCY SURGERY; EPIGASTRIC PAIN; FEMALE; GASTRECTOMY; GASTROINTESTINAL ENDOSCOPY; GASTROINTESTINAL STROMAL TUMOR; HEMATEMESIS; HUMAN; MALE; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT INDICATION; TUMOR VOLUME;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTINEOPLASTIC AGENTS; BIOPSY, NEEDLE; CHI-SQUARE DISTRIBUTION; EGYPT; FEMALE; FOLLOW-UP STUDIES; GASTRECTOMY; GASTROINTESTINAL STROMAL TUMORS; GASTROSCOPY; HOSPITALS, UNIVERSITY; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; PIPERAZINES; PROSPECTIVE STUDIES; PYRIMIDINES; RISK ASSESSMENT; SAUDI ARABIA; STOMACH NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 77349126631     PISSN: 17439191     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijsu.2009.09.016     Document Type: Article

References (32)

1. Igwilo O.C., Byrne M.P., Nguyen K.D., and Atkinson J. Malignant gastric stromal tumors: unusual metastatic patterns. South Med J 96 5 (2003) 512-515
2. Mazu M.T., and Clark H.B. Gastric stromal tumors. Reappraisal of histogenesis. Am J Surg Pathol 7 (1983) 507-519
3. Fletcher C.D., Berman J.J., Corless C., Gorsein F., Lasota J., and Longley B.J. Diagnosis of gastrointestinal stromal tumors consensus approach. Hum Pathol 33 (2002) 459-465
4. Demtteo R.P., Lewis J.J., Leung D., Mudan S.S., Woodruff J.M., and Brennan m. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 231 (2000) 51-58
5. Pierie J.P., Choudry U., Muzikansky A., Yeap B.Y., Souba W.W., and Ott M.J. The effect of surgery and grade on outcome of gastrointestinal stromal tumors. Arch Surg 136 4 (2001) 383-389
6. Saied G.M., Mohsen A.A., El-Nahas Y.I., Sebaie M.E., Nada A.M., Ezzeldeen M.K., et al. Clinical and pathologic characteristics of gastrointestinal stromal tumors in 11 Egyptian patients: implications for surgical management at Cairo University hospitals. KEJ Clin-Oncol NM Vol 1 No.2 (2005). www.7igcc.com.br Presented at 7th IGCC 2007, Sao Paolo Brazil
7. Durham M.M., Gow K.W., Shehata B.M., Katzenstein H.M., Lorenzo R.L., Ricketts R.R., et al. Gastrointestinal stromal tumors arising from the stomach: a report of three children. J Pediatr Surg 39 10 (2004) 1495-1499
8. Miettinen M., Sobin L.H., and Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol 29 (2005) 52-68
9. Cruz Jr. R.J., Vincenzi R., Ketzer B.M., Cecilio A.L., and Cepeda L.A. Spontaneous intratumoral bleeding and rupture of giant gastric stromal tumor (>30 cm) in a young patient. World J Surg Oncol 6 (2008) 76
10. Antoch G., Kanja J., Bauer S., Kuehl H., Renzing-Koehler K., Schuette J., et al. Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors. J Nucl Med 45 3 (2004) 357-365
11. Yokoi K., Yamashita K., Tanaka N., Kyouno S., Ishikawa N., Seya1 T., et al. Gastrointestinal stromal tumor of the stomach diagnosed preoperatively. J Nippon Med Sch 68 5 (2001) 435-441
12. Alabraba E., Bramhall S., O'Sullivan B., Mahon B., and Taniere P. Insulinoma co-existing with gastric GIST in the absence of neurofibromatosis-1. World J Surg Oncol 7 (2009) 7-18. http://www.wjso.com/content/7/1/18
13. O'Reilly M.S., Holmgren L., Shing Y., Chen C., Rosenthal R.A., Moses M., et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79 (1994) 315-328
14. Karimi K.M., McNatt S.S., Rizvi I.A., Cassim R.S., McFadden D.W., and Williams H.J. When GIST can cause massive hemorrhage. Contem Surg 64 7 (2008)
15. Mehta R.M., Sudheer V.O., John A.K., Nandakumar R.R., Dhar P.S., Sudhindran S., et al. Spontaneous rupture of giant gastric stromal tumor into gastric lumen. World J Surg Oncol 3 (2005) 11
16. GCS: Adjuvant imatinib improves survival in patients with GIST. Gastrointestinal cancers symposium, January 25-27, Orlando, Florida. Abstract 8; 2008.
17. Bucher P., Egger J., Gervaz P., Ris F., Weintraub D., Villiger P., et al. An audit of surgical management of gastrointestinal stromal tumors (GIST). Eur J Surg Oncol 32 3 (2006) 310-314
18. Mussi C., Ronellenfitsch U., Jakob J., Tamborini E., Reichardt P., Casali P.G., et al. Post-imatinib surgery in advanced/metastatic GIST: is it worthwhile in all patients?. Ann Oncol (2009) Jul 23. [Epub ahead of print]
19. Liu C.L., Huang M.J., Lin S.C., Chang K.M., and Tzen C.Y. Neo-adjuvant STI571 therapy for high-risk gastrointestinal stromal tumor. ANZ J Surg 74 (2004) 289-290
20. Joensuu H., Roberts P.J., Sarlomo-Rikala M., Andersson L.C., Tervahartiala P., Tuveson D., et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 344 (2001) 1052-1056
21. Bümming P., Andersson J., Meis-Kindblom J.M., Klingenstierna H., Engstrom K., Stierner U., et al. Neoadjuvant, adjuvant and palliative treatment of gastrointestinal stromal tumors (GIST) with imatinib: a centre-based study of 17 patients. Br J Cancer 89 (2003) 460-464
22. Katz D., Segal A., Alberton Y., Jurim O., Reissman P., Catane R., et al. Neoadjuvant imatinib for unresectable gastrointestinal stromal tumor. Anti Canc Drugs 15 (2004) 599-602
23. Haller F., Detken S., Schulten H.-J., Happel N., Gunawan B., Kuhlgatz J., et al. Surgical management after neoadjuvant imatinib therapy in gastrointestinal stromal tumors (GISTs) with respect to imatinib resistance caused by secondary KIT mutations. Ann Surg Oncol 14 (2007) 526-532
24. Hohenberger P., Bauer S., Schneider U., Pinlk D., Dirsch O., Schuette J., et al. Tumor resection following imatinib pretreatment in GI stromal tumors. Proc Annu Meet Am Soc Clin Oncol 22 (2003) 818 [Medline]
25. Andtbacka R.H., Ng C.S., Scaife C.L., Cormier J.N., Hunt K.K., Pisters P.W., et al. Surgical resection of gastrointestinal stromal tumors after treatment with imatinib. Ann Surg Oncol 14 1 (2007 Jan) 1-2
26. Langer C., Gunawan B., Schüler P., Huber W., Füzesi L., and Becker H. Prognostic factors influencing surgical management and outcome of gastrointestinal stromal tumours. Br J Surg 90 (2003) 332-339
27. Raut C.P., and Bertagnolli M.M. Controversies in the surgical management of GIST in the era of imatinib. Oncology 23 1 (2009 Jan) 74-76 69
28. Loughrey M.B., Mitchell C., Mann G.B., Michael M., and Waring P.M. Gastrointestinal stromal tumor treated with neoadjuvant imatinib. Clin Pathol 58 7 (2005 July) 779-781
29. Veneri D., Franchini M., and Bonora E. Imatinib and regression of type 2 diabetes. N Engl J Med 352 (2005) 1049-1050
30. Elliott M.A., Mesa R.A., Tefferi A., Burton C., Azzi A., and Kerridge I. Adverse events after imatinib mesylate therapy. N Engl J Med 346 (2002) 712-713
31. Grimpen F., Yip D., McArthur G., Waring P., Goldstein D., Loughrey M., et al. Resistance to imatinib, low-grade FDG-avidity on PET, and acquired KIT exon 17 mutation in gastrointestinal stromal tumor. Lancet Oncol 6 (2005) 724-726
32. Haller F., Gunawan B., von Heydebreck A., Schwager S., Schulten H.J., Wolf-Salgo J., et al. Prognostic role of E2F1 and members of the CDKN2A network in gastrointestinal stromal tumors. Clin Cancer Res 11 (2005) 6589-6597